Bibliography

Ame92

American College of Chest Physicians-Society of Critical Care Medicine Consensus Conference.
Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis.
Crit Care Med, 20:864-75, 1992.

Buc94

T. G. Buchman.
file:/home/adrian/documents/texstuff/bibs/papers/1994/buchman1994/buchman1994.dvi Manipulation of stress gene expression: A novel therapy for the treatment of sepsis.
Crit Care Med, 22(6):901-3, June 1994.

DLJ⁺03

J. F. Dhainaut, P. F. Laterre, J. M. Janes, G. R. Bernard, A. Artigas, J. Bakker, H. Riess, B. R. Basson, J. Charpentier, B. G. Utterback, J. L. Vincent, and Recombinant Human Activated Protein C Worldwide Evaluation in Sepsis (PROWESS) Study Group.
Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial.
Intensive Care Med, 29(6):894-903, June 2003.

RFPC⁺95

M. S. Rangel-Frausto, D. Pettet, M. Costigan, T. Hwang, C. S. Davis, and R. P. Wenzel.
The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study.
JAMA, 273:117-23, 1995.